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Effects of Oral 
Physostigmme in Alzheimer’s Disease 
Yaakov Stern, PhD,”? Mary Sano, PhD,* and hchard Mayeux, MD”t 
Previous studies of oral physostigmine in the treatment of Alzheimer’s disease have: (1) assumed physastigmine is 
effective only in mildly affected patients; (2) relied on an initial “dose-finding” phase to determine the most effective 
dose and excluded nonresponders; and ( 3 )  primarily assessed memory. We examined the response of 22 patients to six 
different daily dosages of oral physostigmine, using selective reminding tests that were administered twice daily. Nine 
patients had a “best” doselday (mode = 13 mglday), which was used in a subsequent double-blind crossover study. The 
other 13 were given the highest tolerated dose. The selective reminding test and a full neuropsychological battery 
were given during the drug and placebo periods. As a group, the 22 patients improved significantly on the Wechsler 
Adult Intelligence Scale-Revised Digit Symbol subtest and a shape cancelation task ( p  < 0.05). Nine patients showed 
improved performance on the selective reminding test during physostigmine treatment, and 9 showed no response; 4 
patients performed better during placebo treatment. Dose finding did not help in predicting response in the crossover 
study; only 2 of the 9 who showed improvement had a best dose. Dementia severity did not predict crossover response. 
This suggests that: (1) physostigmine as administered had no pronounced effect on memory in Alzheimer’s disease; (2) 
oral physostigmine produces no greater benefits on memory in mildly than in moderately demented patients; (3) 
response in a dose-finding phase does not predict response in double-blind crossover; and (4)  Digit Symbol and 
cancelation tasks may be more sensitive than memory tests to the effects of oral physostigmine. 
Stern Y, Sano M, Mayew R: Effects of oral physostigmine in Alzheimer’s disease. 
Ann Neurol 22:306-310, 1987 
Physostigmine has been considered a promising agent 
for the treatment of Alzheimer’s disease (AD). Investi- 
gators have reported a small, but statistically signifi- 
cant, improvement in patient performance when oral 
physostigmine (OP) was administered 116, 22). How- 
ever, negative findings have also been reported IS). 
We attempted to address three major procedural is- 
sues in the study of this medication: 
1. The effective dose of physostigmine has been 
defined by an inverted U-shaped function, such that 
lower or higher dosages are not as effective as those at 
the median level E3, 7, 18, 22). Many studies have 
applied this observation by using a titration or dose- 
finding phase to determine the optimal dosage for use 
during a crossover with placebo (e.g. 122)). Patients 
who did not show the expected dose-response curve 
have often been excluded from crossover trials { 16, 
227. This procedure could bias the results of the cross- 
over study, increasing the probability of finding some 
drug effect. We investigated the presence of an in- 
verted U-shaped function in patients’ response to OP. 
However, all patients were included in a subsequent 
double-blind crossover study, comparing performance 
on OP to performance on placebo. 
2. It could be assumed that physostigmine is more 
effective in patients with less severe dementia 122). 
This is based on its presumed mode of action: it in- 
hibits the breakdown of synaptically released acetyl- 
choline as opposed to increasing the amount of ace- 
tylcholine available. We assessed this concept by 
including patients who were variably affected by de- 
mentia and comparing their relative response to OP. 
3. Most studies have concentrated on assessing phy- 
sostigmine’s effect on measures of memory, but other 
cognitive functions might also benefit E8, 17). We in- 
cluded tests of a wide range of intellectual function to 
investigate this possibility. 
Methods 
Subjects 
Twenty-two patients with probable AD were selected and 
gave informed consent for this study. Average patient age 
was 67.1 years ( t 8.4); age at onset, 64.0 (k 8.5); education, 
15.0 (&3.7). The average score on the modified Mini- 
Mental State Examination (mMMS) was 41.0 ( t  8.3). In our 
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experience, the average mMMS score in nondemented el- 
derly people is 52.3 (54.3). All patients were required to 
meet the criteria for primary degenerative dementia of the 
American Psychiatric Association’s Diagnostic and Statistical 
Manual {1J as well as NINCDS-ADRDA criteria for “prob- 
able” AD 1151. In addition, patients were screened for their 
ability to recall a minimum of three words on several trials of 
the selective reminding test, described below. The overall 
reaction of patients to testing was also assessed because it can 
be stressful. Those who could not tolerate this procedure 
were not entercd into the study. Twelve patients were elimi- 
nated for these reasons. 
Selective Reminding Test 
The primary measure of memory in this study was a selective 
reminding test (SRT) {4}. In this list-learning task, the sub- 
ject attempts to recall a list of 12 words after they have been 
read to him. After each recall attempt, the words not recalled 
are repeated and the subject is asked to attempt again to 
recall the entire list. This procedure is repeated for a total of 
twelve recall trials. 
Three measures of SRT performance were derived: (1) 
total recall-the total of all words recalled on all trials (max- 
imum score = 144, 12 words x 12 trials); (2) long-term 
retrieval-words recalled on two successive trials (without an 
intervening reminder) were considered to have been re- 
trieved from long-term storage on these two and all follow- 
ing trials; and (3) intrusions-wrong words were corrected 
the first time the patient made the error but were scored as 
intrusion errors for each use thereafter. 
Because this study involved repeated use of the SRT, 17 
different versions were used. Each consisted of words 
derived from unrelated categories. Ten versions have been 
described previously, and their relative equivalence has been 
established 112). The remaining forms were constructed to 
contain words of equivalent frequency of usage 1131 and 
were tested to ensure that they were comparable in re- 
peated-measure reliability studies. 
Proceduw 
DOSE FINDING. After an initial day of baseline testing, OP 
dosage was increased daily for 5 days. The following total 
daily doses were all administered on a dosage schedule of 
every 2 hours, starting at 9 :OO A.M.: 2 mg (x6), 2.5 mg 
( x 6), 3 mg ( x 5), 3.5 mg ( x 4), and 4 mg ( x  4). Patients 
were monitored daily for potential side effects. The SRT was 
administered twice daily at standard times, one-half hour af- 
ter administration of OP. The SRT performance of each 
patient was assessed to determine if the means of the three 
SRT performance measures were consistently better on one 
particular daily dosage. If a patient had a “best” daily dosage, 
then that was used for the subsequent double-blind cross- 
over study. Otherwise, the highest dose tolerated without 
side effects was used. 
DOUBLE-BLIND CROSSOVER STUDY. All patients from the 
dose-finding phase participated in the double-blind crossover 
study. After a 1-day washout period, patients received either 
OP or placebo for 3 days. This was followed by a 1-day 
washout period, and then patients were crossed over to the 
alternate drug or placebo for the second 3-day period. The 
SRT was again administered twice daily. On the third day of 
each crossover period, the following battery of neuro- 
psychological tests was administered: the Wechsler Adult 
Intelligence Scale-Revised (WAIS-R) Digit Symbol subtest 
[25}, Wechsler Memory Scale Logical Memory (immediate 
and 10-minute delay), Visual Recall and Associate Learning 
subtests 1241, Rosen Drawing Test [19], mMMS 19, 141, 
controlled word association test 121, and category-naming 
test {lo}. In addition, two types of cancelation tasks were 
administered. One involved the detection of a specific shape 
within a shape array while another used letter triads as a 
target for detection 1201. This test battery was chosen to 
assess a range of functions that are affected in probable AD. 
Alternate versions of the Wechsler Memory, controlled 
word association, and category-naming tests were used; the 
order of administration of alternate forms was held constant 
because drug/placebo order was randomized across patients. 
Alternate versions of the other tests were not used because, 
in our experience, performance is not affected by repeated 
testing in patients with probable AD. 
Results 
Aduetse Effects 
The most common side effects were dizziness and 
nausea. These were sufficient to terminate the dose- 
finding phase, before the maximum dosage was 
reached, in 8 patients. In all instances, reducing the 
dosage eliminated these effects. 
Dose$ nding Phase 
Correlations between the scores obtained from the 
two SRTs administered at each dosage during the 
dose-finding phase were calculated to investigate the 
stability of SRT performance. At baseline (before drug 
administration), the correlation of total score and of 
long-term recall on the two tests was significant (r  = 
0.91 for both, p < O.Ol), but the correlation of intru- 
sion scores did not reach significance. On other daily 
dosages, all SRT values correlated significantly. 
In grouped data, mean SRT performance at differ- 
ent dosages of OP appeared to have the inverted U- 
shaped function, with maximal performance at 3 to 3.5 
mg every 2 hours (Figure). Each patient’s performance 
was evaluated by two independent raters to determine 
whether this U-shaped function was present. Nine pa- 
tients showed the pattern. In the remaining 13, there 
was no regular dose-response relationship. In 3 of 
these 13 patients there was still a particular daily dos- 
age that yielded the best SRT performance. In the 
other 10, there was no best dosage, and the highest 
dose tolerated without side effects was used for the 
subsequent double-blind crossover trial. 
Double-Blind Crossover Study 
SRT MEASURES. Possible patient improvement on 
SRT measures during the drug period was investigated 




0 2 2.5 3 3.5 4 
Dose (mg) 
4 5  t,: 
~~ ~ 
Relationship of total recall scores on the selective reminding test to  
individual doses received during the dose-finding phase. Trian- 
gies degict standurd ewors ofthe mean. 
Table 1 .  Selective Reminding Test Scores During the Drug 
and Placebo Phases of the Double-Blind Crossover Study 
in 22 Patients 
Placebo Drug 
Selective Reminding Test Mean SD Mean SD 
Total recall 56.6 14.6 57.6 14.6 
Long-term retrieval 22.2 12.3 22.5 14.4 
Intrusions 5.8 6.9 6.1 6.1 
using Student's t tests, comparing the difference be- 
tween SRT scores derived from the first and second 
crossover periods in the two drug-placebo sequence 
groups (i.e., those who received drug first and those 
who received placebo first) I l l ,  231. Paired t tests for 
evaluating changes in performance between the drug 
and placebo trials, as well as repeated-measure analysis 
of variance (ANOVAs), were also employed. There 
were no significant differences between the two condi- 
tions (Table 1). Tests for carryover effects did not 
show significance. To control for possible carryover 
effects, the same analyses were repeated using only 
SRT performance on day 3 of drug and placebo condi- 
tions; again, there were no significant differences be- 
tween the conditions. N o  difference in performance 
as a function of the order of administration of drug 
and placebo was noted. To investigate the relative 
efficiency of OP treatment for patients with mild ver- 
sus moderate dementia, patients were stratified into 
Table 2 .  Neuropsychological Test Scores in the Drug 
and Placebo Phases of thtb Double-Blind Crossover Study 
in 22 Patients 
~~~ ~ 
Placebo D w  
Test Mean SD Mean SD 
mMMS 41.0 8.3 40.8 8.3 
WMS (immediate recall) 
Logical Memory 3.3 1.2 3.8 1.4 
Visual Memory 3.3 3.1 3.3 2.3 
Paired Associates 6.1 2.4 7.3 2.2 
Logical Memory 0.7 0.9 0.8 0.8 
Visual Memory 0.4 1.0 1.0 1.6 
Paired Associates 2.2 1.1 1.6 0.9 
WAIS-R Digit Symbol 6.0 3.8 6.6 3.7" 
(age-scaled score) 
CFL (mean) 11.8 4.3 10.3 4.9 
Category naming (mean) 11.5 4.9 11.6 4.4 
Rosen Drawing Test 10.5 3.1 10.3 2.7 
Cancelations (sec) 
Letters 123.2 39.6 131.2 68.4 
Shapes 116.5 109.0 103.0 65.4" 
WMS (delayed recall) 
~~~ ~ ~ 
"Drug-placebo means were significantly different at p < 0.05. 
mMMS = modified mini-mental state; WAIS-R = Wechsler Adult 
Intelligence Scale-Revised; CFL. = Controlled Word Association; 
WMS = Wechsler Memory Scale. 
two groups, according to their performance on the 
mMMS. There was no difference in the relative im- 
provement between drug and placebo conditions in 
these two groups. 
The performance of individual patients was evalu- 
ated by two independent raters who were blinded to 
drug status, to determine whether all three SRT mea- 
sures were consistently superior in one of the two con- 
ditions. Nine patients showed improved performance 
with OP treatment, 9 had no consistent difference in 
performance between the two conditions, and 4 had 
better performance on placebo. 
NEUROPSYCHOLOGIW BATTERY. Changes in per- 
formance on the neuropsychological battery were in- 
vestigated using ANOVA for repeated measures 
(Table 2). Performance on the WAIS-R Digit Symbol 
subtest and the shape cancelation test was significantly 
better during the drug condition. No differences were 
noted in performance on other tests. 
REIATIONSHIP BETWEEN DOSE-FINDING AND DOU- 
BLE-BLIND CROSSOVER PERFORMANCE. The utility 
of the dose-finding phase for predicting improvement 
during double-blind crossover was investigated. Only 3 
of the patients who showed a response to O P  had been 
judged to have a U-shaped dose-response pattern, and 
only 1 additional patient had had a best daily dosage 
during dose finding. 
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DISEASE SEVERITY AND OP RESPONSE. Baseline 
neuropsychological values of responders and nonre- 
sponders were compared to determine if these two 
groups differed in the severity of their dementia. Mean 
values for all neuropsychological test scores were com- 
parable in the two groups. 
Discussion 
This study suggests that OP may slightly improve intel- 
lectual function in patients with probable AD. On the 
primary dependent measure used in this study, the 
SRT, there was no significant difference between per- 
formance on placebo and drug. Although the number 
of patients in this study was relatively small, the num- 
ber was sufficient to detect a change as small as one- 
third a standard deviation (or approximately 5 % )  in 
SRT scores at an alpha level of 0.05 with a power of 
80% [CJ. Several patients were classified as OP re- 
sponders on the basis of consistent improvement on 
SRT measures, but changes in scores were often slight 
and it is not clear that they imply improvement in “real 
life” function. 
WAIS-R Digit Symbol performance and perfor- 
mance on a shape cancelation task were significantly 
better on OP than placebo. Both of these tests require 
speeded performance and tap aspects of attention and 
visuospatial ability. Poor performance on these tasks is 
not indicative of a specific cognitive or anatomic 
deficit. Still, these findings suggest that it is important 
to assess functions other than memory when evaluating 
the efficacy of OP. Improvement in constructional 
tasks and on a scale designed to assess the severity of 
probable AD have also been reported with physostig- 
mine [lb, 171, and attention improved with cholino- 
mimetics C18). 
Other investigators have relied on a dose-finding 
phase to determine an optimal dosage of physostig- 
mine, and in some studies, patients who did not have 
an “optimal” dose were not included in subsequent 
placebo-controlled investigations (e.g., 1221). This 
selective elimination of patients clearly can bias subse- 
quent studies. We included patients in the double- 
blind crossover phase regardless of their performance 
on a dose-finding phase and found that the dose- 
finding phase was not predictive of later performance. 
We also used higher doses of OP than have been re- 
ported previously. It might be more useful simply to 
determine the highest dose that each patient can toler- 
ate without side effects and then use that dosage for 
placebo-controlled studies. 
One source of variability in assessing patients’ op- 
timal drug doses might have been differences in drug 
absorption after administration. All patients were hos- 
pitalized throughout the entire study and ate at stan- 
dard times each day; dietary effects were probably 
minimal. However, central nervous system effects of 
OP can vary between patients 1221 and this was not 
assessed. 
It has been assumed that physostigmine does not 
increase the synthesis of acetylcholine but instead 
maintains whatever acetylcholine is present in the syn- 
aptic cleft. Given this presumed mode of action, the 
drug should be most effective in patients with more 
intact cholinergic systems, that is, patients with rela- 
tively mild dementia. We studied patients suffering 
from varying degrees of dementia and found no differ- 
ence in OP response between mildly and moderately 
affected patients. In fact, a few patients who began 
with baseline neuropsychological scores in the lower 
range showed the most marked improvement. This 
probably cannot be attributed to a “ceiling” effect in 
the patients with more intact mental functioning, since 
all patients were defective on the SRT in comparison 
to normative data derived from age-matched healthy 
control subjects. Still, the more demented patients did 
have more room for improvement on these measures. 
Another study, using intramuscularly administered 
physostigmine, reported greater improvement in more 
severely demented patients 12 1 J. 
This study suggests that: (1) OP as administered has 
no substantial effect on memory; (2) OP has no greater 
beneficial effect on memory in mildly than in moder- 
ately demented patients; (3) response in a dose-finding 
phase does not predict response in double-blind cross- 
over; and (4)  Digit Symbol or cancelation tasks may be 
more sensitive than memory tests to the effects of OP. 
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